SciSparc surged over 40% today, driven by policy relaxation in the psychedelic drug treatment field — recent administrative orders have opened up clinical advancement space, creating emotional resonance across the entire sector.
However, SciSparc's core pipeline is cannabinoid therapy, which differs from the classic psychedelic drug route. This rally is more due to sector linkage rather than company-specific catalysts.
Even after the +40% move, its market cap remains very small with low liquidity. The risk of chasing the rally in the short term is significant. Whether trading volume can continue to expand is the only reference for judging sustainability.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
